Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Capital Expenditures: 2020-2024

Historic Capital Expenditures for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Dec 2024 value amounting to $20.0 million.

  • Day One Biopharmaceuticals' Capital Expenditures fell 103.05% to -$1.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$34.7 million, marking a year-over-year decrease of 162.83%. This contributed to the annual value of $20.0 million for FY2024, which is 8828.57% up from last year.
  • As of FY2024, Day One Biopharmaceuticals' Capital Expenditures stood at $20.0 million, which was up 8,828.57% from $224,000 recorded in FY2023.
  • In the past 5 years, Day One Biopharmaceuticals' Capital Expenditures registered a high of $20.0 million during FY2024, and its lowest value of $26,000 during FY2022.
  • For the 3-year period, Day One Biopharmaceuticals' Capital Expenditures averaged around $6.8 million, with its median value being $224,000 (2023).
  • Data for Day One Biopharmaceuticals' Capital Expenditures shows a peak YoY skyrocketed of 8,828.57% (in 2024) over the last 5 years.
  • Yearly analysis of 4 years shows Day One Biopharmaceuticals' Capital Expenditures stood at $92,000 in 2020, then reached $26,000 in 2022, then surged by 761.54% to $224,000 in 2023, then soared by 8,828.57% to $20.0 million in 2024.